|
|
|
|
Office Locations:
|
900 Larkspur Landing Circle Suite 150
Larkspur, CA 94939
Phone: 415-877-4887
Fax: 415-567-0091
| |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
Foresite Capital invests between $10 million and $50 million per investment in emerging healthcare companies with disruptive late-stage products with large market opportunities in therapeutics, devices, diagnostics, and services. Since inception in 2011, Foresite has invested in more than 11 transformative companies spanning therapeutics, devices and diagnostics. In April of 2014, the firm announced the closing of Foresite Capital Fund II, which was oversubscribed and closed with $300 million in capital commitments. Fund II follows Foresite Capital Fund I, a $100 million fund that closed in January 2013. Foresite Capital has $3.5 billion in assets under management.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
| Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Amelia Stoj | |
| |
CCO and Assistant General Counsel | |
| Dennis D. Ryan | |
MBA, CPA | |
CFO & Managing Director | |
| Dorothy Margolskee | |
MD | |
Managing Director | |
| Jim Tananbaum | |
MD | |
Founder & CEO | |
| Shannon Bergstedt | |
| |
Principal & Venture Partner | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
03/26/2026
|
Pinnacle Medicines
|
PA
|
$89,000,000
|
Series B
|
02/24/2026
|
Slate Medicines
|
NC
|
$130,000,000
|
Series A
|
02/18/2026
|
Korsana Biosciences
|
MA
|
$175,000,000
|
Seed and Series A
|
02/03/2026
|
Midi Health
|
CA
|
$100,000,000
|
Series D
|
09/25/2025
|
Thyme Care
|
TN
|
$97,000,000
|
Series D
|
09/22/2025
|
Avenzo Therapeutics
|
CA
|
$60,000,000
|
Series B
|
|
|
|
|
|
- Foresite (VSTM) holds 3,146,631 shares, reporting 3.6% stake - Stock Titan
- On Its 15th Anniversary, Foresite Capital Looks Ahead - Genetic Engineering and Biotechnology News
- Foresite Capital buys Alumis (ALMS) shares worth $7m - Investing.com
- Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private ...
- Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Fi...
- Serena Ventures, Foresite join $100M for women’s health unicorn Midi - Tech Funding News
- Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - The Motley Fool
- China’s biopharma advance draws financial investment - Pharma Voice
- Porsche's EV cancellations, Oura's $10.9b valuation, Empower's semiconductor raise - Axios
- Secretive Project Prometheus takes VC Bob Nelsen beyond just health care - statnews.com
|
|
|